PharmaTalkRadio

During the preclinical science plenary session from 2017's Immuno-Oncology 360° conference, Dr Charles Drake's talks about "Sequencing of Combination Agents." 

Dr Drake is Director, Genitourinary Oncology and Co-Director Immunotherapy Associate Director, Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center. Previously, he was an associate professor of oncology, urology and immunology at the Johns Hopkins School of Medicine. He also serves as Co-Director of the Prostate Cancer Multidisciplinary Clinic. His areas of expertise include immunotherapy and the diagnosis and treatment of cancers of the prostate, kidney, bladder and testes.

Dr Drake graduated with a BS in electrical engineering and MS in biomedical engineering from Rutgers University in Piscataway, NJ. He then received a PhD in immunology from the National Jewish Center for Immunology, and in 1997 completed an MD at the University of Colorado Health Sciences Center. He conducted an internal medicine residency on the Osler Service at Johns Hopkins, and in 2002 he completed a fellowship in medical oncology, also at Johns Hopkins. He joined the Johns Hopkins faculty as an assistant professor in 2002.

Save the date for the 4th annual IO360° conference, taking place February 7-9, 2018  in New York City.

At 2016's Rational Combinations 360° meeting, Dr Patrick Hwu of MD Anderson Cancer Center delivered a keynote address on the future outlook behind combination immunotherapy. Dr Hwu addresses innovations behind combination therapy, specifically focusing on what’s next after checkpoint combinations and whether combination of adoptive T-cell therapy and anti-checkpoint inhibitor therapies are the next wave.

Dr Hwu serves as a lead advisor for the 2nd annual Rational Combinations 360° meeting, which takes place June 28-29, 2017, at the The New York Academy of Medicine. Preview the program agenda, including Dr Hwu's plenary session on "DE-RISKING OF COMBINATION IMMUNOTHERAPIES."

We are delighted to bring the Patients as Partners US event to Europe on February 6-7 in London. We would like to thank our European attendees at the US conference for challenging and encouraging us to bring the conference to Europe. The goal of creating patient centricity as the ecosystem within pharma can not be achieved without patient involvement. 

Patients as Partners Europe is accredited by Patients Included and addresses what matters most to patients to enable them to engage in clinical research.

Patients as Partners EU is co-produced with patients, industry, academia, government and nonprofit organizations to establish a well-rounded program that addresses the needs of all stakeholders seeking to implement and advance patient involvement across the entire clinical development continuum.

Each session seeks to put ideas into action and must demonstrate the what, where, when and how behind the topic. This radio blog post provides a seven minute overview on what to expect at the conference. For more information about the conference, visit, www.theconferenceforum.org.

The 3rd annual DPharm Europe: Disruptive Innovations to Advance Clinical Trials event is led by Co-Chairs Dr Sue Collier (GSK) and Dr Jeff Kasher (Patients Can’t Wait).  This radio blogcast gives a five minute overview of the event, which presents global case studies on:

Real World Clinical Trial Strategies and ResultsNew Leadership in Driving Clinical Trial InnovationStrategies to Validate the Siteless TrialCommunity Outreach and Education in Clinical TrialsNew Financial ModelsPatient Involvement and EngagementBrexit Update and Potential Impact on R&DProtocol SimulationAdaptive Trial Model 

DPharm EU takes place at the Millennium Hotel in London on February 8-9, 2017. For more information, visit www.theconferenceforum.org

The 3rd annual Immuno-Oncology 360° event takes place February 1-3, 2017 in NYC.  Lead advisors, Dr Axel Hoos (GSK) and Dr James Gulley (NCI) co-present a program that provides a  360-degree approach addressing the most-up-to-date information regarding business aspects, clinical advancements and scientific data that will help accelerate clinical trials and FDA approval, ultimately transforming the way cancer is treated. In this brief radio blog post, get a five minute overview on what to expect at IO360 2017! For more information on the entire event and speaking faculty, visit, www.theconferenceforum.org

Members of the DPharm team engage in an informal conversation to highlight what's happening in innovation and the latest thinking to disrupt clinical trials at the 6th annual event. Also discussed is a brief history of how this conference dedicated to applying disruptive thinking to clinical trials came to be. This conversation is well worth listening to if you plan to attend DPharm or want to get a sense of the quality and depth this program brings to clinical trial executives.

DPharm takes place September 20-21, 2016 at the Fairmont Copley Plaza Hotel in Boston. Also featured on September 19 is a full day on Mobile Applications to Enhancing Clinical Trials.

DPharm Link for More information or to Register:

http://theconferenceforum.org/conferences/disruptive-innovations-us/overview/

Host: Valerie Bowling, Executive Director, DPharm

Guests:

Meredith Sands, Executive Director, Business Development, DPharm

Elizabeth Bard, Business Development Director, DPharm

Pfizer’s “Blue Sky” approach to transforming clinical research in Parkinson’s disease is an inspiring example of patient-centric innovation. Conference Forum's, Valerie Bowling welcomes co-host, Ed Miseta, Clinical Leader.com in a discussion with members of Pfizer’s "Blue Sky" team. Together they discuss the vision, goals and journey in taking a new approach to advancing drug development. More specifically, the Blue Sky team talks about their partnership with IBM, (first of its kind) decisions on how to use a device in a trial, real time data collection, an 1800s house for a 21st Century research and more. 

Co-Hosts: 

Valerie Bowling, Executive Director, The Conference Forum

Ed Miseta, Chief Editor, Clinical Leader and Contributing Writer, Life Science Leader

Guests: 

Stephen Amato, PhD, Project Manager, BlueSky, Pfizer

David Caouette, MBA, Senior Director, Strategy and Operations Lead, BlueSky and Quantitative Medicine, Pfizer 

 

Daniel Karlin, MD, Senior Director, Quantitative Medicine, Clinical Lead, BlueSky, Pfizer

Both DrsDavid Caouette and Daniel Karlin are co-presenting at the DPharm conference on September 20th in Boston. For more information go to www.theconferenceforum.org.

This discussion provides helpful approaches for Chief Medical Officers (CMOs) and other R&D leadership in biotech on how to communicate effectively in times of good, bad or unexpected news. Also discussed in this program are factors to evaluate for the discontinuation of a program. Dr Mark Weinberg, Chief Medical Officer and Managing Director of Halloran Consulting Group will be joined by Dr Lee Allen, CMO, Argos Therapeutics to discuss strategic communication strategies CMOs/R&D leadership can utilize to effectively deliver unexpected or difficult news.

 More specifically:

How do you communicate successfully?How does a CMO manage an unexpected realization?Tips on being an advocate and skeptic for your programsFlexibility and decision making with dataScenario planningTips on communicating to the publicEvaluating factors for discontinuing a programRationalizing your portfolio? Who decides?

Guests:

Lee Allen, MD, PhD, CMO, Argos Therapeutics

Mark Weinberg, MD, MBA, CMO and Managing Director, Halloran Consulting Group

Producer:

Valerie Bowling,  Executive Director, PharmaTalk Radio & The Conference Forum

Recommended Conference: The CMO and R&D Biotech Leadership Summit, Nov 14-15 in San Francisco. For more info:

http://theconferenceforum.org/conferences/rdbiotechleadershipsummit/overview/

What is the quality, capacity and efficiency of running clinical trials in Puerto Rico? In this discussion we speak with Dr Myrto Lee, Director, PwC'sStrategy&, UK and Dr Kosmas Kretsos, Executive Director of the Puerto Rico Consortium for Clinical Investigation to learn about key initiatives and outcomes so far to make running clinical trials more attractive in Puerto Rico. For more information about conductingclinical trials in Puerto Rico, please visit www.PRCCI.org.

Why consider Puerto Rico for clinical trials?Status of new sites to expand clinical trial networksStatus of a central coordinator with sites to reduce bureaucracy e.g. central IRB, central invoicingPatient access and costsPatient engagementAccess to new technologiesTraining

Guest Host:

Dr Myrto Lee, Director, PwC's Strategy&, UK

Guest:

Dr Kosmas Kretsos, Executive Director, PRCCI (Puerto Rico Consortium for Clinical Investigation), Puerto Rico

Producer:

Valerie Bowling, Executive Director, the Conference Forum

Frustrated that a promising therapy for a rare cancer was sitting in a freezer due to the lack of a relatively modest amount of funding, author Alexander Masters helped lead a campaign to crowd-fund a clinical trial: the result, iCancer.org.uk. The money required was indeed raised by a wealthy individual primarily, in return for being in the trial. At DPharm Europe, Pfizer's Craig Lipset interviewed on stage Alexander to share his story. We are delighted to present the journey and latest updates on PharmaTalk Radio. 

The story of the formation of iCancer.org.uk and the Oncolytic Virus FundAn alternative way to make clinical trials more accessibleEthical and moral issuesA possible disruptive and sustainable model for other neglected medicines

The next DPharm: Disruptive Innovations to Advance Clinical Trials event takes place September 20-21 in Boston. DPharm Europe is scheduled for February 8-9, 2017 in London. For more information about these events or our Immuno-Oncology events, visit, www.theconferenceforum.org.

Producer:

Valerie Bowling

Executive Director, Conference Forum & Pharma Talk Radio

Guest Host:

Craig Lipset, MBA

Head of Clinical Innovation, R&D,Pfizer

Guest:

Alexander Masters

Author, Medical Campaigner and Co-Founder,iCancer.org.uk